Cytokinetics Inc (NAS:CYTK)
$ 48.98 -10.25 (-17.31%) Market Cap: 5.14 Bil Enterprise Value: 6.35 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Cytokinetics Inc Investor Event Transcript

Nov 23, 2020 / 01:30PM GMT
Release Date Price: $16.07 (+0.50%)
Operator

Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics Conference Call. At this time, I would like to inform you that this call is being recorded. (Operator Instructions) I would now like to turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.

Diane Weiser
Cytokinetics, Incorporated - SVP of Corporate Communications & IR

Good morning, everyone, and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will begin with an overview of today's announcement and next steps related to omecamtiv mecarbil. Then we'll open the call to questions, and Robert will be joined by Fady Malik, Executive Vice President of R&D; Libby Schnieders, Senior Vice President of Business Development; Ching Jaw, Senior Vice President and Chief Financial Officer; and Mark Schlossberg, Senior Vice President, Legal & General Counsel.

Please note that portions of the following discussion, including our responses to questions, contain

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot